IPO OncoMed (OMED) is a clinical development-stage biopharmaceutical company focused on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells, or CSCs. Their approach has been to target CSCs, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs. OncoMed's product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
No comments:
Post a Comment